Medication therapy management involves using clinical pharmacists to review a patient’s use of prescription medications, over-the-counter products and supplements to evaluate potential therapy problems and maximize the effectiveness of treatment. Because research has indicated that not only does MTM improve quality, but it can lead to significant cost savings, CMS has required that Part D plans, including Medicare Advantage plans which have Part D coverage, identify certain classes of beneficiaries who could benefit from MTM and do an outreach to engage those patients in a comprehensive evaluation of their drug therapies. But a new analysis from Avalere finds that many beneficiaries are not getting the benefit of MTM. (Avalere Analysis) Avalere says that about 25% of beneficiaries are eligible for an MTM intervention, but only 11% received any kind of review. In looking at the top ten Part D carriers, MTM enrollment varied from 4.6% to 17.5%, but the actually receipt of a comprehensive medication review was between 2% and 74% of the enrolled beneficiaries. Overall, a very small 1% of Part D enrollees received a CMR, much lower than the number who could likely have benefited from one. Medicare Advantage plans did a better job, with enrollees in those being three times more likely to get a CMR and many of those had an actual intervention to improve care, such as a call to a prescriber or a change in therapy. Part of the reason for the low use of MTM is that beneficiaries have to agree to participate and many don’t want to or don’t understand the potential benefit. CMS could help by providing incentives for participation. But Part D sponsors have little incentive to encourage MTM, as it is not currently a STAR measure. They get some pressure from CMS, but until there are some teeth in the program, the plan sponsors won’t likely really make an effort to use MTM.
Medication Therapy Management in Part D
By Kevin RocheAugust 22, 2014Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 25, 2023
Coronamonomania Lives Forever, Part 201
Tired of March Madness? A boringly refreshing dip into some CV-19 research summaries is recommended.
March 24, 2023
The CDC Is a Font of Methodological and Statistical Error
Several times in the last three years I and others have pointed out serious flaws…
March 24, 2023
A Couple of Health Care Notes
A couple of pieces of health care research focus on high health care spending and…